Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
PARDES BIOSCIENCES, INC. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/17/2023 SC 13E3/A Form SC 13E3/A - Going private transaction by certain issuers: [Amend]
08/17/2023 SC 14D9/A Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
08/17/2023 SC 13E3 Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
08/14/2023 SC 13G Beryl Capital Management LLC reports a 7.8% stake in Pardes Biosciencs, Inc.
08/04/2023 10-Q Quarterly Report for the period ended June 30, 2023
07/28/2023 SC 13E3 Form SC 13E3 - Going private transaction by certain issuers:
07/28/2023 SC 14D9 Form SC 14D9 - Solicitation, recommendation statements:
07/28/2023 SC TO-T Form SC TO-T - Tender offer statement by Third Party:
07/17/2023 SC TO-C Form SC TO-C - Written communication relating to an issuer or third party:
07/17/2023 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
07/17/2023 SC14D9C Form SC14D9C - Written communication relating to third party tender offer:
07/17/2023 8-K Quarterly results
05/18/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Re: Separation Agreement and General Release of Claims",
"Appointment of Consultant; Services. As of the Effective Date, Company appoints Consultant and Consultant hereby accepts appointment as consultant to the Company. In this capacity, Consultant shall perform the services set forth on Exhibit 1 . Consultant and Company shall work together to delineate the scope of each project and the timeline and deliverables related thereto. Consultant is expected to work no more than 12 hours per month for the Company through July 31, 2023, and then no more than 6 hours per month thereafter, which the parties acknowledge is less than 20% of Consultant’s average weekly service level with the Company over the 36 months prior to the end of the Term. 2. Term; Termination. Upon the Separation Agreement becoming effective, this Consulting Agreement will be effec..."
05/05/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/05/2023 8-K Quarterly results
04/21/2023 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
04/21/2023 8-K Quarterly results
04/20/2023 ARS Form ARS - Annual Report to Security Holders:
04/20/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/20/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/03/2023 8-K Results of Operations and Financial Condition, Cost Associated with Exit or Disposal Activities, Regulation FD Disclosure, Ot...
Docs: "Pardes Biosciences Announces Top-line Results from Phase 2 Trial Evaluating Pomotrelvir for the Treatment of COVID-19 Pomotrelvir did not meet the primary endpoint measured by proportion of participants below the limit of detection for infectious SARS-CoV-2 on day 3 of treatment with pomotrelvir vs. placebo Otherwise healthy, vaccinated adults without risk factors for progression to severe disease experienced rapid clearance of SARS-CoV-2 virus and evidence of rapid alleviation of targeted and key COVID-19 symptoms independent of treatment arm Based on these results, Pardes to suspend further clinical development of pomotrelvir and explore a range of strategic alternatives CARLSBAD, Calif. April 03, 2023 – Pardes Biosciences, Inc. , a clinical-stage biopharmaceutical company developing a n..."
02/14/2023 SC 13G/A RA CAPITAL MANAGEMENT, L.P. reports a 0% stake in Pardes Biosciences, Inc.
02/08/2023 SC 13G/A BML Investment Partners, L.P. reports a 7.8% stake in Pardes Biosciences Inc
01/23/2023 SC 13G Lynx1 Capital Management LP reports a 5% stake in Neoleukin Therapeutics, Inc.
01/23/2023 EFFECT Form EFFECT - Notice of Effectiveness:
01/18/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
01/18/2023 EFFECT Form EFFECT - Notice of Effectiveness:
12/30/2022 SC 13G BML Investment Partners, L.P. reports a 7.8% stake in Pardes Biosciences Inc
12/05/2022 SC 13D/A FS Development Holdings II, LLC reports a 24.5% stake in Pardes Biosciences, Inc.
11/07/2022 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
11/07/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/07/2022 8-K Quarterly results
Docs: "Pardes Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update Phase 2 trial evaluating PBI-0451 for treatment of COVID-19 ongoing, with data expected in first quarter of 2023 CARLSBAD, Calif. November 7, 2022 – Pardes Biosciences, Inc. , a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel oral antiviral drug candidate for the treatment and prevention of COVID-19 in adult and pediatric patients, today reported financial results for the third quarter ended September 30, 2022 and provided a business update. “We made significant progress in our pursuit to bring a stand-alone, easily administered oral treatment to patients suffering from COVID-19, highlighted by the commencement of our PBI-0451 Phase 2 trial in September 2022..."
10/17/2022 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
10/17/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy